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Objectives: Inhalation of antibiotics is a standard treatment for chronic infection
with Pseudomonas aeruginosa (PA) in patients with cystic ﬁbrosis (CF). Inhalation
on alternate months is thought to prevent the emerging of resistance of PA for
tobramycin. Tobramycin for inhalation is prescribed in our centre for continuous
use >10 years. We hypothesize that this treatment does not alter susceptibility of
PA to tobramycin.
Methods: In this prospective study with retrospective control measurements we
collected sputum samples over 3 to 5 years from 60 CF patients, treated with
tobramycin or colistin inhalation therapy, with chronic PA infection. Using high-
range Etest® strips susceptibility of PA was tested. The MENSURA criteria are
applied for predicting the susceptibility to tobramycin.
Results: In 48 patients susceptibility testing for tobramycin is completed and in
47 patients for colistin. Within these patients 22 patients used tobramycin, 26
used colistin. Results were categorised in susceptible, intermediate or resistant.
For tobramycin-users in 16 patients susceptibility did not change, 4 cases changed
from susceptible to intermediate (1) or resistant (3), in 2 patients susceptibility
changed from resistant to susceptible. The likelihood for the susceptibility to
remain unchanged or change to susceptible is 82% (95%CI: 0.66–0.98). Analysing
MICtobra in tobramycin-users showed no signiﬁcant change of MICtobra, with
p = 0.076. Within the 26 patients using colistin, no changes in susceptibility for
colistin were observed.
Conclusion: In this study we could establish that continuous inhalation of to-
bramycin does not lead to increased resistance of PA.
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Objectives: We have recently demonstrated that human rhinovirus (HRV) is associ-
ated with more severe pulmonary exacerbations with greater falls in lung function
and higher inﬂammatory response. Asymptomatic viral carriage is common in the
general population and we aimed to establish whether the presence or absence of
viral symptoms affected exacerbation severity.
Methods: The study group comprised 104 patients who had previously been
identiﬁed as HRV PCR positive exacerbations between Dec 2008 and May 2011.
Their electronic records were reviewed to establish the number of patients who had
presented with viral symptoms at the time when the sample was obtained. Clinical
data was collected to assess the severity of each exacerbation.
Results: 53 of the 104 patients had viral symptoms when the swab was taken. No
signiﬁcant differences were seen between the patients with viral symptoms and those
that were asymptomatic. Speciﬁcally no differences were seen in treatment length,
inﬂammatory markers, recovery of lung function, and the time to next exacerbation.
There was a non-signiﬁcant trend to higher frequencies of HRV group A and lower
frequencies of HRV group C in the patients with viral symptoms.
Conclusion: The identiﬁcation of HRV during an exacerbation is detrimental to the
patient irrespective of viral symptoms.
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Objectives: The clinical epidemiology of CF is evolving and has changed dra-
matically over the past decades. Pulmonary complications play an important role in
aging patients with CF. The knowledge of the microbiological status of patients with
CF is of great importance for therapeutic and hygienic reasons. Certain bacteria,
such as Pseudomonas aeruginosa (Pa) or Burkholderia spp. are known to cause a
more severe course of disease and lower life expectancy. With newer, better and
more specialized microbiological techniques it is possible to detect a higher amount
of pathogens.
Methods: 31 CF centres were involved as part of the benchmarking project.
A prospective data collection was used via the German Muko.dok system. The
parameters FEV1 and BMI were analyzed in terms of microbial and mycological
detection. Results were compared with data from the CFF registry. The following
germs were analyzed: Pa, multidrug-resistant (MDR) Pa, Achromobacter, non-
tuberculous mycobacteria (NTM), Scedosporium spp., MRSA, Burkholderia spp.
250 further bacterial and mycological pathogens were detected in 2012 but the
dignity is largely unknown.
Results: The incidence of documented pathogens was lower except Pa and Achro-
mobacter xylosoxydans compared to the CFF data. In our registry data analyzation
we found a serious high prevalence of (MDR) Pseudomonas aeruginosa, similar
to the published CFF data. In addition, we found the highest incidence of NTM in
our cohort at the age of 17−18 years.
Conclusions: Worrying is the high prevalence of (MDR) Pa and Achromobacter,
similar to the CFF data. The detection of NTM in nearly any patient group supports
the current discussion under CF experts.
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Objectives: Candida albicans has been recently recognized as clinically signiﬁcant
microorganism colonizing the respiratory system in cystic ﬁbrosis (CF) patients.
The aim of this study was to investigate the association between inhaled antibiotics
and C. albicans chronic colonization in CF patients.
Methods: A retrospective cohort study of children with CF born from 1988 to
1996 was performed. Their medical records were reviewed from the ﬁrst time they
attended the CF Center until December 2010. Outcomes were either the occurrence
of C. albicans chronic colonization or their last visit at the CF Center. Chronic
colonization was deﬁned as the presence of C. albicans in more than 50% of cultures
in a given year. A number of possible confounders such as follow-up period, BMI,
pancreatic insufﬁciency, duration of inhaled antibiotic treatment, duration of inhaled
corticosteroid treatment and duration of azithromycin treatment were included in
the multivariate logistic regression analysis in order to identify an independent
association between inhaled antibiotics and C. albicans chronic colonization.
Results: At total, 121 patients were included in the study and 54 (44.6%) developed
chronic colonization during the study period. Multivariate logistic regression anal-
ysis determined the independent effect of inhaled antibiotic treatment on the odds
of chronic colonization (OR 1.112, 95%CI 1.007–1.229, p= 0.036). Moreover, the
role of Body Mass Index (BMI) and azithromycin treatment had a tendency toward
signiﬁcance after adjustment for confounders.
Conclusion: The duration of inhaled antibiotic treatment is associated with C.
albicans chronic colonization in CF patients.
